NCT01842165已完成3 期
The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- The time to progression (TTP) for each target lesion assessed on MRI (or on CT scan if MRI is not possible).
研究概览
简要总结
The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion treatment outcome.
详细描述
This is a feasibility study evaluating the use of 177Lutetium-octreotate in the treatment of advanced refractory Neuroendocrine Tumors.
Objectives of the study:
- Primary (on a lesion basis): To assess the value of the following parameters (obtained through functional and molecular imaging) for predicting the lesion-by-lesion PRRT treatment outcome:
- 18FDG uptake on 18FDG PET/CT
- 68Ga-octreotate uptake on 68Ga-octreotate PET/CT
- Apparent diffusion coefficient on diffusion weighted MRI (for these 3 parameters, absolute values at baseline)
- Tumor dosimetry on post 177Lu-octreotate SPECT/CT after each cycle.
- Secondary (on a patient basis): To generate a patient-based response model based on the previously defined parameters.
- Exploratory (on a lesion basis): To assess the value of the parameters mentioned in the primary objective for predicting the lesion-by-lesion PRRT treatment outcome:
- absolute values of the three imaging parameters and their relative changes after each cycle;
- serial tumor dosimetry on post-177Lu-octreotate SPECT/CT after each cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient-based:
- •Age above or equal to 18 years.
- •Histology-proven advanced GEP-NETs.
- •Disease progression defined as follows (at least one of the following):
- •Radiological disease progression (according to RECIST 1.1) on an MRI or CT over the last 12 months Or
- •Disease progression on a somatostatin receptor-imaging, PET/CT or SPECT/CT over the last 12 months [apparition of new lesion(s) or increase in the transaxial plane diameter of more than 30% on the same imaging modality] Or
- •Both of the following criteria (a+b):
- •clinical progression:
- •sustained (for more than 2 weeks) increase of NET-specific hormonal hypersecretion related symptom frequency by 50% or,
- •sustained (for more than 2 weeks) increase of severity by 1 grade (according to NCI-CTCAE version 4.03).
- •biochemical progression: by increase of NET-specific tumor markers (plasma Chromogranin A, plasma NSE, urine 5-HIAA or other) in two successive measurements.
- •Disease refractory to SSA's and/or standard systemic therapy available in Belgium at the time of inclusion criteria.
- •Long-acting SSAs should be discontinued at least 4 weeks before study treatment start date and, if needed, switched to short-acting analogues which should be stopped 48h before the treatment date.
- •Adequate renal function with GFR ≥ 50 mL/min/1.73m2 (evaluated by 51Cr-EDTA test).
- •Adequate bone marrow function with hemoglobin ≥ 9 g/dL; neutrophil ≥ 1.5·103/μL; platelet count ≥ 100·103/μL.
- •Adequate liver function with total bilirubin ≤ 2 x ULN and transaminases ≤ 5 x ULN, serum albumin > 3 g/dL with normal prothrombin time (> 70%).
- •ECOG Performance Status ≤
- •Women of childbearing potential and men with partners of childbearing potential must agree to use a highly-effective form of contraception for the duration of study participation and up to six months after the end of the treatment. A pregnancy test (serum) must be performed within 4 weeks prior to inclusion for every female patient of childbearing potential and it must be negative.
- •Patient's written informed consent obtained prior to any study procedure.
- •All necessary baseline procedures should be performed within 4 weeks prior to first 177Lu-octreotate injection (D0).
- •Lesion-based:
- •The patient must have at least one target lesion fulfilling all of the below criteria:
- •On the 68Ga-octreotate PET/CT: tumor uptake higher than the physiological liver uptake (grade III or IV of the Rotterdam visual score) in a lesion with longest transaxial plane diameter ≥20mm (measured on the CT, part of the PET/CT);
- •At least one of these lesions morphologically measurable according to RECIST 1.1 and progressive on the MRI (or CT if MRI is not applicable);
- •Target lesion should not have been previously irradiated.
排除标准
- •Resectable tumor with curative intent.
- •Any major surgery within the last 6 weeks prior to inclusion in the study
- •Radiotherapy, chemotherapy, embolization, mammalian target of rapamycin (mTOR)-inhibitors, receptor tyrosine-kinase inhibitors, interferon, or other investigational therapy within the last 12 weeks prior to inclusion in the study.
- •Diffuse bone marrow infiltration on the baseline 68Ga-octreotate PET/CT confirmed by MRI.
- •Prior external beam radiotherapy on kidneys or on more than 25% of bone marrow.
- •Patients with known uncontrolled brain metastases.
- •Patients with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the investigator's opinion, may interfere with completion of the study.
- •Pregnant or lactating patients.
- •Women of childbearing potential and men with partners of child-bearing potential refusing an adequate contraception.
研究组 & 干预措施
177Lu-octreotate therapy
Other
Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
干预措施: Intravenous injection of 177Lu-octreotate (Drug)
结局指标
主要结局
The time to progression (TTP) for each target lesion assessed on MRI (or on CT scan if MRI is not possible).
时间窗: 4 years [Anticipated]
TTP is defined as the time between treatment initiation and objective tumor progression with censoring of patients who die as a result of any cause.
次要结局
- Progression Free Survival(4 years [Anticipated])
- Best morphological response according to RECIST 1.1(4 years [Anticipated])
- Biochemical response (evolution of NET-specific tumoral uptake).(4 years [Anticipated])
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical-imaging study assessing the value of biological parameters obtained through multimodality molecular and functional imaging (differences in 68Ga-octreotate and 18FDG uptake, changes in diffusion weighted magnetic resonance imaging and 177Lu-octreotate dosimetry) for the prediction of treatment outcome in advanced refractory gastroenteropancreatic neuroendocrine tumors.Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative intent.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2012-003666-41-BEJules Bordet Institute52
已完成
不适用
The RE-ENERGIZE study: a RandomisEd trial of ENtERal Glutamine to minimIZE thermal injurySevere thermal burn injuriesInjury, Occupational Diseases, PoisoningBurn injuriesISRCTN92905442Clinical Evaluation Research Unit (CERU) (Canada)200
招募中
3 期
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Advanced Gastroenteropancreatic Neuroendocrine TumorNCT05884255Jiangsu HengRui Medicine Co., Ltd.220
已完成
2 期
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT00382239AstraZeneca153
终止
1 期
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory MalignanciesBladder NeoplasmsMultiple MyelomaLymphomaProstatic NeoplasmsNCT00050687Titan Pharmaceuticals